WuXi PharmaTech announces Management Appointments

China’s WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company, has announced that Dr Steve Yang (pictured) has joined the company as Executive Vice President and Chief Operating Officer. Edward Hu will assume new responsibilities as Chief Investment Officer and remain as Chief Financial Officer.

Dr Yang is a pharmaceutical industry leader recognized for building R&D capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in China and other Asian and emerging markets.

Before joining WuXi, Dr Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, based in Shanghai. Previously, Dr Yang served as Vice President and Head of Asia R&D at Pfizer based in Shanghai, and as Executive Director and head of Pfizer's global R&D strategic management group based in the United States.